Pidala J, Lee SJ, Ahn KW, Spellman S, Wang HL, Aljurf M, et al. Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. Blood. 2014;124:2596–606.
Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007;110:4576–83.
Kasamon YL, Luznik L, Leffell MS, Kowalski J, Tsai H-L, Bolaños-Meade J, et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant. 2010;16:482–9.
Kharfan-Dabaja MA, Labopin M, Ayala E, Bazarbachi A, Blaise D, Vydra J, et al. Significance of degree of HLA disparity using T-cell replete peripheral blood stem cells from haploidentical donors with posttransplantation cyclophosphamide in AML in first complete hematologic remission: a study of the acute leukemia working party of the EBMT. Hemasphere. 2023;7:e920.
Sanz J, Labopin M, Blaise D, Raiola AM, Busca A, Vydra J, et al. Haploidentical stem cell donor choice for patients with acute myeloid leukemia: a study from the ALWP of the EBMT. Blood Adv. 2024;8:2332–41.
Lorentino F, Labopin M, Fleischhauer K, Ciceri F, Mueller CR, Ruggeri A, et al. The impact of HLA matching on outcomes of unmanipulated haploidentical HSCT is modulated by GVHD prophylaxis. Blood Adv. 2017;1:669–80.
Raiola AM, Risitano A, Sacchi N, Giannoni L, Signori A, Aquino S, et al. Impact of HLA disparity in haploidentical bone marrow transplantation followed by high-dose cyclophosphamide. Biol Blood Marrow Transpl. 2018;24:119–26.
Solomon SR, Aubrey MT, Zhang X, Jackson KC, Morris LE, Holland HK, et al. Class II HLA mismatch improves outcomes following haploidentical transplantation with posttransplant cyclophosphamide. Blood Adv. 2020;4:5311–21.
Fuchs EJ, McCurdy SR, Solomon SR, Wang T, Herr MR, Modi D, et al. HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide. Blood. 2022;139:1452–68.
Mehta RS, Cao K, Saliba RM, Al-Atrash G, Alousi AM, Lontos K, et al. HLA factors versus non-HLA factors for haploidentical donor selection. Transpl Cell Ther. 2023;29:189–98.
Crivello P, Heinold A, Rebmann V, Ottinger HD, Horn PA, Beelen DW, et al. Functional distance between recipient and donor HLA-DPB1 determines nonpermissive mismatches in unrelated HCT. Blood. 2016;128:120–9.
Petersdorf EW, Malkki M, O’HUigin C, Carrington M, Gooley T, Haagenson MD, et al. High HLA-DP expression and graft-versus-host disease. N Engl J Med. 2015;373:599–609.
Petersdorf EW, Carrington M, O’HUigin C, Bengtsson M, De Santis D, Dubois V, et al. Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: a retrospective cohort study. Lancet Haematol. 2020;7:e50–e60.
Kramer CSM, Koster J, Haasnoot GW, Roelen DL, Claas FHJ, Heidt S. HLA-EMMA: a user-friendly tool to analyse HLA class I and class II compatibility on the amino acid level. Hla. 2020;96:43–51.
Rimando J, Slade M, DiPersio JF, Westervelt P, Gao F, Liu C, et al. The predicted indirectly recognizable HLA epitopes (PIRCHE) score for HLA class i graft-versus-host disparity is associated with increased acute graft-versus-host disease in haploidentical transplantation with post-transplantation cyclophosphamide. Biol Blood Marrow Transpl. 2020;26:123–31.
Duquesnoy RJ. A structurally based approach to determine HLA compatibility at the humoral immune level. Hum Immunol. 2006;67:847–62.
Duquesnoy RJ. HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. I. Description of the algorithm. Hum Immunol. 2002;63:339–52.
Duquesnoy RJ, Marrari M, Sousa LCDDM, Barroso JRPDM, Aita KMDSU, da Silva AS, et al. 16th IHIW: a website for antibody-defined HLA epitope registry. Int J Immunogenet. 2013;40:54–9.
Rimando J, Slade M, DiPersio JF, Westervelt P, Gao F, Liu C, et al. HLA epitope mismatch in haploidentical transplantation is associated with decreased relapse and delayed engraftment. Blood Adv. 2018;2:3590–601.
Zou J, Ciurea SO, Kongtim P, Yi M, Carmazzi Y, Rondon G, et al. Molecular disparity in human leukocyte antigens is associated with outcomes in haploidentical stem cell transplantation. Blood Adv. 2020;4:3474–85.
Zou J, Wang T, He M, Bolon Y-T, Gadalla SM, Marsh SGE, et al. Number of HLA-mismatched eplets is not associated with major outcomes in haploidentical transplantation with post-transplantation cyclophosphamide: A Center for International Blood and Marrow Transplant Research Study. Transplant Cell Ther. 2022;28:107.e1–e8.
Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–9.
Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, et al. Validation and refinement of the disease risk index for allogeneic stem cell transplantation. Blood. 2014;123:3664–71.
Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl. 2019;25:625–38.
Sullivan KM, Shulman HM, Storb R, Weiden PL, Witherspoon RP, McDonald GB, et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood. 1981;57:267–76.
Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transpl. 2016;22:4–10.
Hurley CK, Kempenich J, Wadsworth K, Sauter J, Hofmann JA, Schefzyk D, et al. Common, intermediate and well-documented HLA alleles in world populations: CIWD version 3.0.0. Hla. 2020;95:516–31.
Tassone G, Santis D, Vukovic I, Downing J, Martinez O, D’Orsogna L. Different eplet software programs give discordant and incorrect results: An analysis of HLAMatchmaker vs Fusion Matchmaker Eplet calling software. HLA. 2020;96:52–63.
Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc: Ser B. 1995;57:289–300.
Geneugelijk K, Thus KA, Spierings E. Predicting alloreactivity in transplantation. J Immunol Res. 2014;2014:159479.
Abboud R, Keller J, Slade M, DiPersio JF, Westervelt P, Rettig MP, et al. Severe cytokine-release syndrome after T cell-replete peripheral blood haploidentical donor transplantation is associated with poor survival and anti-IL-6 therapy is safe and well tolerated. Biol Blood Marrow Transpl. 2016;22:1851–60.
Raj RV, Hamadani M, Szabo A, Pasquini MC, Shah NN, Drobyski WR, et al. Peripheral blood grafts for T cell-replete haploidentical transplantation increase the incidence and severity of cytokine release syndrome. Biol Blood Marrow Transpl. 2018;24:1664–70.
McCurdy SR, Muth ST, Tsai H-L, Symons HJ, Huff CA, Matsui WH, et al. Early fever after haploidentical bone marrow transplantation correlates with class II HLA-mismatching and myeloablation but not outcomes. Biol Blood Marrow Transpl. 2018;24:2056–64.
Imus PH, Blackford AL, Bettinotti M, Luznik L, Fuchs EJ, Huff CA, et al. Severe cytokine release syndrome after haploidentical peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2019;25:2431–7.
Otoukesh S, Elmariah H, Yang D, Clark MC, Siraj M, Ali H, et al. Cytokine release syndrome following peripheral blood stem cell haploidentical hematopoietic cell transplantation with post-transplantation cyclophosphamide. Transpl Cell Ther. 2022;28:111.e1–e8.
Shapiro RM, Kim HT, Ansuinelli M, Guleria I, Cutler CS, Koreth J, et al. Cytokine release syndrome in haploidentical stem cell transplant may impact T-cell recovery and relapse. Blood Adv. 2023;7:4080–8.
Mariotti J, Taurino D, Marino F, Bramanti S, Sarina B, Morabito L, et al. Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide. Cancer Med. 2020;9:52–61.
von dem Borne PA, Kemps-Mols BM, de Wreede LC, van Beek AA, Snijders TJF, van Lammeren D, et al. The degree of HLA matching determines the incidence of cytokine release syndrome and associated nonrelapse mortality in matched related and unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide. Leuk Lymphoma. 2024;65:1270–80.
Abid MB, Hamadani M, Szabo A, Hari PN, Graham MB, Frank MO, et al. Severity of cytokine release syndrome and its association with infections after T cell-replete haploidentical related donor transplantation. Biol Blood Marrow Transpl. 2020;26:1670–8.
Little JS, Shapiro RM, Aleissa MM, Kim A, Chang JBP, Kubiak DW, et al. Invasive yeast infection after haploidentical donor hematopoietic cell transplantation associated with cytokine release syndrome. Transpl Cell Ther. 2022;28:508.e1–e8.
Hsiao M, Chen D, Yaghmour G. An update on investigating the relationship between cytokine release syndrome, graft-versus-host disease, and one-year mortality after haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2020;26:S285–S6.
Hernández-Sánchez A, Cabero A, Fonseca M, Puertas B, Gómez S, Alonso D, et al. CT-169 cytokine release syndrome after peripheral blood haploidentical stem cell transplantation with post-transplant cyclophosphamide: time of onset matters. Clin Lymphoma Myeloma Leuk. 2022;22:S437–S8.
